Skip to content

Riding the Wave | Differentiating Bispecifics and CAR-T for Relapsed Refractory Multiple Myeloma
Expert Consult #2: Eye on the Future in Multiple Myeloma
*Activity Post-Survey & Application for CME Credit*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.What are your credentials? (Required.)
2.What is your community of practice?
3.Compared to the phase 3 CARTITUDE-4 clinical trial, a key difference in demographics of patients enrolled in the phase 3 KarMMa-3 clinical trial is that more than half of patients had which of the following characteristics? 
4.The results of the phase 3 CARTITUDE-4 clinical trial demonstrated which of the following outcomes?
5.Which of the following has been observed in approximately 50% to 70% of patients receiving investigational bi-/trispecific antibodies for relapsed/refractory multiple myeloma? 
6.All of the following are barriers to use of soluble BCMA as a biomarker in clinical practice EXCEPT?  
7.Which of the following types of biomarkers is correctly matched to biomarker routinely used in the management of patients with multiple myeloma? 
EVALUATION FORM
8.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
DIFFERENTIATE pivotal trial results of current and emerging BCMA-directed therapies for RRMM  
INTERPRET the role of prognostic and predictive biomarkers in the management of patients with RRMM 
9.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources provided to me at the educational activity are useful to my practice.
10.Overall, was this activity fair, balanced and free from commercial bias?
11.If no, please explain:
12.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
13.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
14.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
15.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
16.I certify that I have participated in the continuing education activity entitled, "Expert Consult #2: Eye on the Future in Multiple Myeloma" and claim 0.75 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice